Collegium Pharmaceutical, Inc. COLL Debt-to-equity

Debt-to-equity at other companies

AVN

AVNSAVNS

0.2×0.0×

Pacira BioSciences, Inc.PCRX

0.6×+0.2×

BioventusBVS

1.2×-1.1×

OrganonOGN

9.5×-7.0×

Dogwood TherapeuticsDWTX

0×0.0×

Cumberland PharmaceuticalsCPIX

0.3×+0.1×

FAQ

What is Collegium Pharmaceutical, Inc.'s debt-to-equity?

Collegium Pharmaceutical, Inc. (COLL) reported debt-to-equity of 0× in Q2 2026.

How has Collegium Pharmaceutical, Inc.'s debt-to-equity changed year-over-year?

Collegium Pharmaceutical, Inc.'s debt-to-equity decreased by 40.4% year-over-year, from 0× to 0×.

What is the long-term trend for Collegium Pharmaceutical, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Collegium Pharmaceutical, Inc.'s debt-to-equity has grown at a -18.4% compound annual growth rate (CAGR), from 0.1× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.